Table 3.
Comparison of the Most Common Tau Transgenic Models and Other Models with Tauopathy
| Tau transgenic models | |||||
|---|---|---|---|---|---|
| Promoter | Mutation | Begin of tau brain pathology | Phopho-tau in spinal cord | Motor impairment | Reference |
| PrP | P301L | 5 months | Detectable at 5 months | Yes at 6.5 months (hemizygous) | 7 |
| CamK-II (inducible tet-off) | P301L | 2.5 months | n.d. at 2.5 months | Yes at 9.5 months | 9, 28 |
| Thy1.2 | P301L | 3 months | Detectable at 3 months | Yes (muscle atrophy and weakness) | 8 |
| Thy1.2 | P301S | 5 months | Detectable at 5 months | Yes at 5 months (homozygous) | 10 |
| Thy1 | G272V P301L R406W | 1.5 months | Detectable at 1.5 months | No abnormality up to 12 months | 37 |
| CamK-II | R406W | 5 months | Detectable at 5 months | No abnormality up to 23 months | 13 |
| Thy1.2 | G272V P301S | 3 months | Minor traces at 3 to 6 months | No abnormality up to 18 months | Present study |
| APP or PS1 and tau double/triple-transgenic models | |||||
|---|---|---|---|---|---|
| Promoter | Transgene expression | Begin of tau brain pathology | Phopho-tau in spinal cord | Motor impairment | Reference |
| Thy1.2 (Tau, APP), PS1-KI | TauP301LxAPPswxPS1M146V | 12 months | No data available | No data available | 63 |
| PrP (Tau), PrP(APP) | TauP301LxAPPsw | 6 months | 3 months | Yes | 60 |
| Other transgenic models with tau pathology | |||||
|---|---|---|---|---|---|
| Promoter | Targeted gene | Begin of tau brain pathology | Motor impairment | Reference | |
| − | pin1 (−/−) | 2 years | No | 64 | |
| NSE | p25 | 4 months | No paralysis but increased spontaneous locomotor activity | 65 | |
CamK-II, Ca2+-calmodulin-dependent kinase II; KI, knockin; NSE, neuron-specific enolase; n.d., not detectable; Pin1, peptidyl-prolyl cis/trans isomerase 1; PrP, prion protein promotor; (−/−), knockout.